DR-053 Analysis of Cancer Evolutionary Processes
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-053 Analysis of Cancer Evolutionary Processes
We use whole cancer genome sequences to understand the order of mutations in cancer development so that we can infer …
DR-052 Measuring the evolutionary dynamics of positive and negative selection in metastatic cancers
In this project we aim at combining mathematical modelling of tumor evolution with cancer genomic data to measure fundamental evolutionary …
DR-050 Discovery and Clincal Characterization of Cancer Driver Mutations in Noncoding regions
Cancer genomes typically harbor a substantial number of somatic mutations. However, only few of these mutations actually contribute to tumor …
DR-044 A pan-cancer catalogue of the mutational footprint of DNA repair deficiencies and their potential as biomarkers of treatment efficacy
“Cancer develops by accumulation of mutations in the DNA of individual cells. In many patients, DNA repair mechanisms are often …
DR-040 Utilizing neoantigens to treat pancreatic cancer
Pancreatic cancer is the fourth leading cause of cancer-realated deaths in the world. Current therapeutic options including chemo-, radio- and …
DR-037 Precision Cancer Therapy: Profiting from Tumor Specific Defects and Synthetic Lethality in the DNA Damage Tolerance Network
Tumor-specific defect in the DNA repair offer great potential for DNA damage based chemo/radio therapy. Present data implicate that this …
DR-047 Characterizing mutational profiles of anti-cancer drugs
Anticancer drugs can (in)directly interfere with DNA and thereby potentially generate a characteristic pattern of somatic mutations (mutational signature). Identifying …
DR-046 CPCT-02 Breast NAVIGATOR: Non-invasive monitoring of breast cancer therapy using cell-free tumor DNA in blood
Resistance to therapy is one of the main challenges in treatment of metastatic breast cancer. We know that treatment resistance …
DR-045 DR-009 extension: Lung and melanoma genomic profiles
Immunotherapies stimulate the patients own immune system to kill tumor cells. These relatively new therapies have shown impressive treatment results …
DR-043 Pan-cancer quantification of DNA- and retroviruses
Some cancers are the result of viral infections. A novel type of cancer therapy, called immunotherapy, has been shown to …
DR-041 Quantification and characterization of clustered somatic mutations throughout the pan-cancer metastatic landscape using our custom algorithm KatDetect
Cancer is driven by accumulation of single DNA mutations, but also by catastrophic events involving multiple simultaneous changes. One such …
DR-039 Defining the spectrum of structural variation in 2,500 metastatic cancer genomes
Recent whole genome sequencing efforts have identified a broad spectrum of gains and losses of DNA in cancer genomes. This …
Een complete genetische analyse zou onderdeel moeten zijn van de standaarddiagnostiek bij iedere patiënt met kanker. Dat draagt bij aan een beter, afgestemd behandeladvies. Zo verminderen we over- en onderbehandeling, maken we tegelijkertijd de zorg kosten-effectiever en houden we hem betaalbaar.